Search

Osteosarcoma (OS) is a devastating illness with rapid rates of dissemination and a poor overall prognosis, despite aggressive standard-of-care surgical techniques and combination chemotherapy regimens. Identifying the molecular mechanisms involved in disease pathogenesis and progression may offer insight into new therapeutic targets. Defects in mesenchymal stem cell differentiation, abnormal expression of oncogenes and tumor suppressors, and dysregulation within various important signaling pathways have all been implicated in development of various disease phenotypes. As such, a variety of basic science and translational studies have shown promise in identifying novel markers and modulators of these disease-specific aberrancies. Born out of these and similar investigations, a variety of emerging therapies are now undergoing various phases of OS clinical testing. They broadly include angiogenesis inhibitors, drugs that act on the bone microenvironment, receptor tyrosine kinase inhibitors, immune system modulators, and other radio- or chemo-sensitizing agents. As new forms of drug delivery are being developed simultaneously, the possibility of targeting tumors locally while minimizing systemic toxicityis is seemingly more achievable now than ever. In this review, we not only summarize our current understanding of OS disease processes, but also shed light on the multitude of potential therapeutic strategies the scientific community can use to make long-term improvements in patient prognosis. [ABSTRACT FROM AUTHOR]

This study is retrospective analysis of primary and secondary osteogenic tumor's patients who are operated between 2005 and 2010. The study include the patients who were operated between 2005 and 2010. Result of them were identified bone involvement by clinic and pathologic. 9 of the patients were female (42.8%), 11 of them were male (57.2%). The mean age of 34.65 (8-65) and 12 of them (85.7%) benign bone tumors (osteoma, osteoblastoma, fibrous dysplasia and fibroosseoz dysplasia) were found. 2 patients (14.3%) were primary malignant tumor which is originated from bone (osteosarcoma) . Symptoms, clinic-radiologic findings and treatment modalities of patients were discussed with literature. [ABSTRACT FROM AUTHOR]

Benign primary bone tumors are far more common than their malignant counterpart and are encountered in everyday practice. Imaging plays a crucial role in recognition of the nonaggressive nature of these lesions, determining the need for further imaging or follow-up. This article reviews the clinical, demographic, and radiological features of some of the more common entities classified as benign or intermediate (locally aggressive) according to the World Health Organization classification of bone tumors., Competing Interests: Disclosure The authors have nothing to disclose., (Copyright © 2021 Elsevier Inc. All rights reserved.)

Osteosarcoma (OS) is a devastating illness with rapid rates of dissemination and a poor overall prognosis, despite aggressive standard-of-care surgical techniques and combination chemotherapy regimens. Identifying the molecular mechanisms involved in disease pathogenesis and progression may offer insight into new therapeutic targets. Defects in mesenchymal stem cell differentiation, abnormal expression of oncogenes and tumor suppressors, and dysregulation within various important signaling pathways have all been implicated in development of various disease phenotypes. As such, a variety of basic science and translational studies have shown promise in identifying novel markers and modulators of these disease-specific aberrancies. Born out of these and similar investigations, a variety of emerging therapies are now undergoing various phases of OS clinical testing. They broadly include angiogenesis inhibitors, drugs that act on the bone microenvironment, receptor tyrosine kinase inhibitors, immune system modulators, and other radio- or chemo-sensitizing agents. As new forms of drug delivery are being developed simultaneously, the possibility of targeting tumors locallywhile minimizing systemic toxicityis is seemingly more achievable now than ever. In this review, we not only summarize our current understanding of OS disease processes, but also shed light on the multitude of potential therapeutic strategies the scientific community can use to make long-term improvements in patient prognosis., (© 2016 the Journal of Biomedical Research. All rights reserved.)